Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI

Teva Pharmaceuticals, a Medincell partner, has submitted an application to the FDA for marketing authorization of Olanzapine LAI. This monthly treatment is intended for adults with schizophrenia. Its innovation lies in a long-acting subcutaneous injection, designed to improve patient adherence and clinical stability.

FDA approval of the review could occur within two months, followed by an eight-month full review of the dossier. Olanzapine LAI addresses a critical therapeutic need by providing a solution that combines efficacy and practicality for the daily lives of patients with schizophrenia.